Siren Biotechnology, a San Francisco-based gene therapy startup, is raising $5 million through regulation crowdfunding, a method rarely used in biotech but common in tech startups. The campaign is hosted on the WeFunder platform and allows both accredited and non-accredited investors to purchase equity stakes. Founded in 2020, Siren has previously secured $4 million in grants and $28 million in venture funding from investors including Founders Fund and Lux Capital. The company is developing a therapy that combines gene therapy and cancer immunotherapy for high-grade glioma, an aggressive brain cancer. Its lead program is in preclinical testing, with plans to seek regulatory approval for human trials by year-end. CEO and scientific founder Nicole Paulk said, "The scientist in me is just like, 'We're going to run this experiment and see if it works.'" The crowdfunding round has already exceeded WeFunder's $50,000 minimum threshold, with more than a dozen public investors and a $200,000 commitment from KMAK Capital. This initiative aims to supplement traditional funding sources and help early-stage biotech companies like Siren reach key development milestones during a challenging funding environment for gene and cell therapy firms.